[REVISION HISTORY]

Lipoprotein(a) genetic cardiovascular risk research

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-09-26 21:12 UTC → 2026-09-29 01:23 UTC · added ~~removed~~

Analysis of data from three National Institutes of Health trials has identified lipoprotein(a), or Lp(a), as a significant genetic marker for cardiovascular risk. Research indicates that approximately one in five people may have elevated levels of this particle, which is largely determined by the LPA gene rather than lifestyle factors. High levels of Lp(a) are associated with a 64% higher risk of stroke and a 49% higher risk of cardiovascular death. The particle contains apolipoprotein(a), which makes it stickier than standard LDL cholesterol, contributing to arterial plaque buildup and potentially interfering with blood clot dissolution. Despite these findings and updated guidelines from the American Heart Association and the American College of Cardiology recommending lifetime testing, fewer than 1% of people in the United States have been tested for this specific marker, as it is typically not included in standard cholesterol panels. A retrospective cohort study from the Mayo Clinic has expanded the known risks associated with the particle. Analyzing data from 69,214 patients between 1997 and 2026, researchers found that elevated Lp(a) levels are consistently associated with incident venous thromboembolism (VTE). Specifically, patients with levels of 50 mg/dL or higher exhibited a crude VTE rate of 2.8%, compared to 1.9% in those with lower levels. The study tracked documented cases of deep vein thrombosis (DVT) and pulmonary embolism (PE), suggesting a link to venous events that was previously considered uncertain.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.